Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.

Irenaeus S, Schiza A, Mangsbo SM, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ.

Oncotarget. 2017 Jul 31;8(45):78573-78587. doi: 10.18632/oncotarget.19750. eCollection 2017 Oct 3.

2.

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.

Schiza A, Wenthe J, Mangsbo S, Eriksson E, Nilsson A, Tötterman TH, Loskog A, Ullenhag G.

J Transl Med. 2017 Apr 20;15(1):79. doi: 10.1186/s12967-017-1182-z.

3.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM.

Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

4.

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.

Ellmark P, Mangsbo SM, Furebring C, Norlén P, Tötterman TH.

Cancer Immunol Immunother. 2017 Jan;66(1):1-7. doi: 10.1007/s00262-016-1909-3. Epub 2016 Oct 6. Review.

5.

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.

Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH, Ullenhag G.

Br J Cancer. 2016 Apr 12;114(8):872-80. doi: 10.1038/bjc.2016.42. Epub 2016 Mar 31.

6.

Kick-starting the cancer-immunity cycle by targeting CD40.

Ellmark P, Mangsbo SM, Furebring C, Tötterman TH, Norlén P.

Oncoimmunology. 2015 Mar 16;4(7):e1011484. eCollection 2015 Jul.

7.

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P.

Clin Cancer Res. 2015 Mar 1;21(5):1115-26. doi: 10.1158/1078-0432.CCR-14-0913. Epub 2014 Oct 14.

8.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

9.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

10.

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer.

Sandin LC, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27400.

11.

Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma.

Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O, Hemminki A, Loskog AS, Tötterman TH, von Euler H.

J Immunother. 2013 Jul-Aug;36(6):350-8. doi: 10.1097/CJI.0b013e31829d8a1b.

PMID:
23799414
12.

T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.

Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS.

Immunology. 2013 Oct;140(2):211-9. doi: 10.1111/imm.12129.

13.

Cytomegalovirus-specific CD4 and CD8 T cell responses in infants and children.

Lidehäll AK, Engman ML, Sund F, Malm G, Lewensohn-Fuchs I, Ewald U, Tötterman TH, Karltorp E, Korsgren O, Eriksson BM.

Scand J Immunol. 2013 Feb;77(2):135-43. doi: 10.1111/sji.12013.

14.

Rapid expansion of T cells: Effects of culture and cryopreservation and importance of short-term cell recovery.

Sadeghi A, Ullenhag G, Wagenius G, Tötterman TH, Eriksson F.

Acta Oncol. 2013 Jun;52(5):978-86. doi: 10.3109/0284186X.2012.737020. Epub 2012 Nov 6.

PMID:
23126547
15.

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.

Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M.

Biomaterials. 2012 Sep;33(26):6230-9. doi: 10.1016/j.biomaterials.2012.05.011. Epub 2012 Jun 9.

PMID:
22687756
16.

Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy.

Ullenhag GJ, Sadeghi AM, Carlsson B, Ahlström H, Mosavi F, Wagenius G, Tötterman TH.

Cancer Immunol Immunother. 2012 May;61(5):725-32. doi: 10.1007/s00262-011-1182-4. Epub 2011 Dec 23.

PMID:
22202906
17.

Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.

Lindqvist CA, Christiansson LH, Thörn I, Mangsbo S, Paul-Wetterberg G, Sundström C, Tötterman TH, Simonsson B, Enblad G, Frisk P, Olsson-Strömberg U, Loskog AS.

Immunology. 2011 Jul;133(3):296-306. doi: 10.1111/j.1365-2567.2011.03439.x. Epub 2011 Apr 5.

18.

Large-scale bioreactor expansion of tumor-infiltrating lymphocytes.

Sadeghi A, Pauler L, Annerén C, Friberg A, Brandhorst D, Korsgren O, Tötterman TH.

J Immunol Methods. 2011 Feb 1;364(1-2):94-100. doi: 10.1016/j.jim.2010.11.007. Epub 2010 Nov 25.

PMID:
21111743
19.

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH.

Clin Cancer Res. 2010 Jun 15;16(12):3279-87. doi: 10.1158/1078-0432.CCR-10-0385. Epub 2010 May 4.

20.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.

J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.

PMID:
20445343
21.

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.

Danielsson A, Elgue G, Nilsson BM, Nilsson B, Lambris JD, Tötterman TH, Kochanek S, Kreppel F, Essand M.

Gene Ther. 2010 Jun;17(6):752-62. doi: 10.1038/gt.2010.18. Epub 2010 Mar 11.

PMID:
20220781
22.

Resolvin E1 reduces proinflammatory markers in human pancreatic islets in vitro.

Lund T, Mangsbo SM, Scholz H, Gjorstrup P, Tötterman TH, Korsgren O, Foss A.

Exp Clin Endocrinol Diabetes. 2010 Apr;118(4):237-44. doi: 10.1055/s-0029-1241825. Epub 2010 Jan 29.

PMID:
20119897
23.

Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.

Mangsbo SM, Sanchez J, Anger K, Lambris JD, Ekdahl KN, Loskog AS, Nilsson B, Tötterman TH.

J Immunol. 2009 Nov 15;183(10):6724-32. doi: 10.4049/jimmunol.0902374. Epub 2009 Oct 28.

24.

Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood.

Georgopoulos LJ, Elgue G, Sanchez J, Dussupt V, Magotti P, Lambris JD, Tötterman TH, Maitland NJ, Nilsson B.

Mol Immunol. 2009 Sep;46(15):2911-7. doi: 10.1016/j.molimm.2009.07.008. Epub 2009 Aug 8.

25.

CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.

Sund F, Lidehäll AK, Claesson K, Foss A, Tötterman TH, Korsgren O, Eriksson BM.

Clin Transplant. 2010 May-Jun;24(3):401-9. doi: 10.1111/j.1399-0012.2009.00976.x. Epub 2009 Feb 14.

PMID:
19222507
26.

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas.

Leja J, Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V.

Mod Pathol. 2009 Feb;22(2):261-72. doi: 10.1038/modpathol.2008.174. Epub 2008 Oct 24.

27.

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.

Vikman S, Sommaggio R, De La Torre M, Oberg K, Essand M, Giandomenico V, Loskog A, Totterman TH.

Acta Oncol. 2009;48(3):391-400. doi: 10.1080/02841860802438495.

PMID:
18855160
28.

High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.

Forsberg O, Carlsson B, Malmström PU, Ullenhag G, Tötterman TH, Essand M.

Prostate. 2009 Jan 1;69(1):70-81. doi: 10.1002/pros.20858.

PMID:
18814178
29.

The T-cell pool is anergized in patients with multiple sclerosis in remission.

Fransson ME, Liljenfeldt LS, Fagius J, Tötterman TH, Loskog AS.

Immunology. 2009 Jan;126(1):92-101. doi: 10.1111/j.1365-2567.2008.02881.x. Epub 2008 Jun 24.

30.

Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.

Carlsson B, Sadeghi A, Bengtsson M, Wagenius G, Tötterman TH.

J Immunother. 2008 Sep;31(7):633-43. doi: 10.1097/CJI.0b013e3181822097.

PMID:
18600181
31.

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.

von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Tötterman TH.

J Immunother. 2008 May;31(4):377-84. doi: 10.1097/CJI.0b013e31816a812d.

PMID:
18391758
32.

Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells.

Forsberg O, Carlsson B, Tötterman TH, Essand M.

Br J Haematol. 2008 Apr;141(2):188-99. doi: 10.1111/j.1365-2141.2008.07026.x. Epub 2008 Feb 26.

PMID:
18307565
33.

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.

Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH.

J Immunother. 2008 Jan;31(1):34-42.

PMID:
18157010
34.

CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.

Vikman S, Giandomenico V, Sommaggio R, Oberg K, Essand M, Tötterman TH.

Cancer Immunol Immunother. 2008 Mar;57(3):399-409. Epub 2007 Aug 24.

PMID:
17717663
35.

CD40L - a multipotent molecule for tumor therapy.

Loskog A, Tötterman TH.

Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):23-8. Review.

PMID:
17346201
36.

Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy.

Carlsson B, Forsberg O, Bengtsson M, Tötterman TH, Essand M.

Prostate. 2007 Mar 1;67(4):389-95.

PMID:
17219382
37.

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines.

Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmström PU, Tötterman TH.

J Urol. 2007 Jan;177(1):353-8.

PMID:
17162090
38.
39.

Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1.

Essand M, Vikman S, Grawé J, Gedda L, Hellberg C, Oberg K, Totterman TH, Giandomenico V.

J Mol Endocrinol. 2005 Dec;35(3):489-501.

PMID:
16326835
40.

Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein.

Carlsson B, Hou M, Giandomenico V, Nilsson B, Totterman TH, Essand M.

J Infect Dis. 2005 Dec 1;192(11):1912-20. Epub 2005 Oct 21.

PMID:
16267762
41.

Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.

Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmström PU, Tötterman TH.

Lab Anim. 2005 Oct;39(4):384-93.

PMID:
16197705
42.

Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors.

Loskog A, Ninalga C, Tötterman TH.

Cancer Immunol Immunother. 2006 May;55(5):588-97. Epub 2005 Sep 21.

PMID:
16175400
43.

T cell control of primary and latent cytomegalovirus infections in healthy subjects.

Lidehall AK, Sund F, Lundberg T, Eriksson BM, Tötterman TH, Korsgren O.

J Clin Immunol. 2005 Sep;25(5):473-81.

PMID:
16160916
44.

The immunotherapy of prostate and bladder cancer.

Totterman TH, Loskog A, Essand M.

BJU Int. 2005 Oct;96(5):728-35.

45.

An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer.

Cheng WS, Dzojic H, Nilsson B, Tötterman TH, Essand M.

Cancer Gene Ther. 2006 Jan 1;13(1):13-20.

PMID:
16052227
46.

Gene expression in midgut carcinoid tumors: potential targets for immunotherapy.

Vikman S, Essand M, Cunningham JL, de la Torre M, Oberg K, Tötterman TH, Giandomenico V.

Acta Oncol. 2005;44(1):32-40.

PMID:
15848904
47.

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

Ninalga C, Loskog A, Klevenfeldt M, Essand M, Tötterman TH.

J Immunother. 2005 Jan-Feb;28(1):20-7.

PMID:
15614041
48.

Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation.

Heijnen IA, Barnett D, Arroz MJ, Barry SM, Bonneville M, Brando B, D'hautcourt JL, Kern F, Tötterman TH, Marijt EW, Bossy D, Preijers FW, Rothe G, Gratama JW; European Working Group on Clinical Cell Analysis.

Cytometry B Clin Cytom. 2004 Nov;62(1):1-13.

49.

Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP.

Carlsson B, Tötterman TH, Essand M.

Prostate. 2004 Oct 1;61(2):161-70.

PMID:
15305339
50.

A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.

Cheng WS, Kraaij R, Nilsson B, van der Weel L, de Ridder CM, Tötterman TH, Essand M.

Mol Ther. 2004 Aug;10(2):355-64.

Supplemental Content

Loading ...
Support Center